- Talis Biomedical Announces Exploration of Strategic Alternatives and Cost Reduction Plan to Preserve Cash
- Talis Biomedical Announces Second Quarter 2023 Financial Results and Business Update
- Talis Biomedical to Report Second Quarter 2023 Financial Results and Provide a Business Update on August 10, 2023
- Talis Biomedical Announces Andrew Lukowiak, Ph.D., as President and Chief Scientific Officer (CSO)
- New Data Presented at the Infectious Disease Society for Obstetrics and Gynecology (IDSOG) Annual Meeting Differentiate Talis Biomedical’s Women’s and Sexual Health Product Menu
- Talis Biomedical Regains Compliance with Nasdaq Minimum Bid Price Requirement
- Talis Biomedical Announces 1-for-15 Reverse Stock Split
More ▼
Key statistics
On Thursday, Talis Biomedical Corp (TLIS:NAQ) closed at 9.10, -2.36% below its 52-week high of 9.32, set on Mar 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.16 |
---|---|
High | 9.16 |
Low | 8.99 |
Bid | 8.60 |
Offer | 14.33 |
Previous close | 9.10 |
Average volume | 8.31k |
---|---|
Shares outstanding | 1.82m |
Free float | 1.67m |
P/E (TTM) | -- |
Market cap | 16.58m USD |
EPS (TTM) | -34.26 USD |
Data delayed at least 15 minutes, as of May 02 2024 18:01 BST.
More ▼